BioXcel Therapeutics (BTAI) EBT Margin (2022 - 2026)
BioXcel Therapeutics (BTAI) posted quarterly EBT Margin of 6898.06% for Q1 2026, up 132397.0% year-over-year from N/an in Q1 2025, and down 150.02% quarter-over-quarter from 2758.98% in Q4 2025.
BioXcel Therapeutics (BTAI) EBT Margin (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' EBT Margin history runs 5 years deep, the most recent figure standing at 6898.06% for Q1 2026.
- In Q1 2026, EBT Margin rose 132397.0% year-over-year to 6898.06%; the TTM figure through Mar 2026 stood at 8682.5% (down 545107.0% YoY), while the FY2025 annual figure was 10339.41%, up 99298.0% from the prior year.
- EBT Margin for Q1 2026 stood at 6898.06%, down from 2758.98% in the prior quarter.
- The five-year high for EBT Margin was 1841.03% in Q2 2024, with the low at 71336.55% in Q4 2022.
- The 5-year median for EBT Margin is 8629.44% (2024), against an average of 17327.79%.
- The sharpest annual moves came in 2023 and 2025: EBT Margin surged 6575384 bps in 2023, then slumped 1469563 bps in 2025.
- BioXcel Therapeutics' EBT Margin stood at 71336.55% in 2022, then surged by 92 bps to 5582.71% in 2023, then surged by 65 bps to 1978.42% in 2024, then plunged by 39 bps to 2758.98% in 2025, then slumped by 150 bps to 6898.06% in 2026.
- Business Quant data shows BTAI's EBT Margin at 6898.06% in Q1 2026, 2758.98% in Q4 2025, and 18289.8% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -10.99% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 35.09% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 13.34% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 47.58% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -1.70% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 16.91% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 4.09% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | BioXcel Therapeutics | 24.25 Mn | 24.25 Mn | 160,000.00 | -7,867.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7,867.58% |
| Mar 31, 2026 | -6,898.06% |
| Dec 31, 2025 | -2,758.98% |
| Sep 30, 2025 | -18,289.80% |
| Jun 30, 2025 | -16,536.67% |
| Mar 31, 2025 | -8,222.02% |
| Dec 31, 2024 | -1,978.42% |
| Sep 30, 2024 | -8,629.44% |
| Jun 30, 2024 | -1,841.03% |
| Mar 31, 2024 | -4,608.76% |
| Dec 31, 2023 | -5,582.71% |
| Sep 30, 2023 | -15,996.77% |
| Jun 30, 2023 | -13,130.85% |
| Mar 31, 2023 | -41,384.95% |
| Dec 31, 2022 | -71,336.55% |
| Sep 30, 2022 | -42,721.90% |